by Dr. Pat Soon-Shiong - Executive Chairman Immunity Bio - Learn more here - https://immunitybio.com/founders-vision/

Our NK snd T cells have a highly specialized receptor on their surface called IL15. Ankitiva is a protein we have manufactured that is given as a subcutaneous injection and binds to this IL 15 receptor on the surface of these cancer killing cells, and when this happens these protective and cancer killing NK and T cells expand in huge numbers and become activated. That’s the Bioshield. That’s what is needed to kill cancer and to drive what we call Memory T cells. And we measure the levels in your body of these NK and T cells by a simple blood test called ALC. The Absolute Lymphocyte Count.

The ALC levels have been hidden in plain sight. So ask your doctor what are your ALC levels ..” What is my ALC” should be a routine question ….and don’t be surprised if your doctor had not looked at it before or know about the term ALC ..It’s not your doctor’s fault because until now, in the history of medicine there was nothing they could prescribe to fix an ALC if it was low for this medical diagnosis called LYMPHOPENIA.

We could fix anemia so we routinely looked at hemoglobin levels and oncologists routinely check the Red blood cell levels after chemo therapy. We could fix what we called neutropenia, so oncologists routinely looked at neutrophil levels called ANC ( absolute neutrophil count). So our doctors are very familiar with ANEMIA and NEUTROPENIA all measurable and treatable.

But until now we could not fix LYMPHOPENIA as measured by a low ALC below 1000 cells - the most dangerous diagnosis of low NK cells and T cells - so we ignored ALC ( Absolute lymphocyte count) present in the same test, called the CBC.

Hope this explanation of all these medical acronyms helps to explain why ALC has been a “ mystery” for so long …,both to our healthcare professionals as well as the patients who need to know.

Today it is not just measurable but treatable.

Anktiva is today only approved for a small subset of bladder cancer. We have completed our trials that took years to do across 10 different cancers and showed when we increase ALC in patients regardless of tumor types including patients with lung cancer, the results of combining Anktiva changes the course of survival regardless of the cancer type. That makes sense since we were treating the immune system and our NK and T cells kill ALL CANCERS regardless of tumor type. Details of this study has been submitted for peer review.

More to come. Education through X!

Connecting the dots of a 35 year quest with the epiphany starting from my earliest publication while at UCLA in 1990 that NK cells are the key immune cells to survival and now perhaps even the key to longevity.

Link to original post - https://x.com/DrPatSoonShiong/status/1987211878553284818?s=20

NK cells are the key immune cells to survival and now perhaps even the key to longevity.

Comments